Drugs / JS212
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06888830 | Apr 2025 → Dec 2027 expected | cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07503756 | Apr 2026 → Dec 2027 expected | colorectal cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07480733 | Apr 2026 → Nov 2027 expected | cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07518160 | Apr 2026 → Apr 2028 expected | lung cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07484724 | Apr 2026 → Jun 2027 expected | esophageal squamous cell carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07309276 | Jan 2026 → Nov 2027 expected | lung cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06868836 | Mar 2025 → Sep 2026 overdue | non-small cell lung carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07714304 | Jul → Nov 2026 expected | — | Huan Zhou | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-14 | Shanghai Junshi Bioscience Co., Ltd. | Regulatory 君实生物宣布美国FDA批准JS212（EGFR/HER3 ADC）临床试验申请 junshipharma.com ↗
北京时间12月14日，君实生物（1877.HK，688180.SH）宣布，公司旗下EGFR/HER3双特异性抗体偶联药物（代号：JS212）用于治疗晚期实体瘤的临床试验申请获得美国食品药品监督管理局（FDA）批准。 |
| 2025-05-08 | BioDlink Biopharm Co., Ltd. | Regulatory BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate biodlink.com ↗
BioDlink congratulates Junshi Biosciences on receiving IND approval from China’s NMPA for JS212, the company’s first bispecific ADC. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-14 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物宣布美国FDA批准JS212（EGFR/HER3 ADC）临床试验申请 junshipharma.com ↗ |
| 2025-05-08 | BioDlink Biopharm Co., Ltd. | BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate biodlink.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07714304 ↗ |
| Known as | JS212 for Injection | “JS212 for Injection:” NCT07518160 ↗ |
| Route | Intravenous | “JS212 (4.2mg/kg or another SMC-selected dose, intravenous, on day 1)” NCT06868836 ↗ |